Work for Capricor Therapeutics, Inc.?
Claim Your Profile
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Capricor Therapeutics, Inc. has reached its limit for free report views.
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders.
